Fig. 1From: A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancerKaplan–Meier estimates of (a) time-to-progression (TTP) and (b) overall survival (OS) among patients with metastatic gastric cancer treated with cetuximab, irinotecan, folinic acid and 5-fluorouracil (FOLFIRI)Back to article page